Latest Pharma Insights
White House Pulls Overton’s US FDA Commissioner Nomination Despite Cassidy Seeing Path
Outgoing Senate Health, Education, Labor and Pensions Committee Chair Bill Cassidy said Heidi Overton’s nomination for FDA commissioner died because of the White House, not a lack of votes.
HBW Insight - November 18, 2026
Outgoing Senate Health, Education, Labor and Pensions Committee Chair Bill Cassidy said Heidi Overton’s nomination for FDA commissioner died because of the White House, not a lack of votes.
HBW Insight - November 18, 2026
Proposed US Rule May Boost Supplement Industry Chances In ‘Race To Market’ For New Ingredients
FDA doesn’t signal end to “race to market” supplement industry is up against to introduce additional dietary ingredients before they’re approved as drugs but suggests ingredients already used in drugs can be shown to qualify for exemptions to “exclusion clause.”
HBW Insight - November 18, 2026
FDA doesn’t signal end to “race to market” supplement industry is up against to introduce additional dietary ingredients before they’re approved as drugs but suggests ingredients already used in drugs can be shown to qualify for exemptions to “exclusion clause.”
HBW Insight - November 18, 2026
Harry’s Marketer Questions NARB Appeals Process Amid FTC Referral
Mammoth Brands’ reluctance to comply with NARB’s recommendations in an appeal brought forward by Procter & Gamble will result in the self-regulatory appeals body referring the matter to the FTC.
HBW Insight - November 18, 2026
Mammoth Brands’ reluctance to comply with NARB’s recommendations in an appeal brought forward by Procter & Gamble will result in the self-regulatory appeals body referring the matter to the FTC.
HBW Insight - November 18, 2026
Deal Watch: Lilly Partners With Stipple On Cell-Surface Epitope Binders For Cancer
With details on deals between Sanofi/Seawolf, AstraZeneca/Omniose, CorMedix/Heron, UCB/Cradle, plus technology transfer news and deals in brief.
Scrip - November 17, 2026
With details on deals between Sanofi/Seawolf, AstraZeneca/Omniose, CorMedix/Heron, UCB/Cradle, plus technology transfer news and deals in brief.
Scrip - November 17, 2026
Finance Watch: Big AI Promises Captivate Venture Investors As Isomorphic Raises $5bn
Private Company Edition: Isomorphic Labs, after a $2.1bn series B round in May, raised a $5bn series C round for its AI drug discovery and development efforts. Also, Flagship revealed new global health and AI initiatives, Seawolf launched with $100m and Marrow emerged with $173m.
Scrip - November 17, 2026
Private Company Edition: Isomorphic Labs, after a $2.1bn series B round in May, raised a $5bn series C round for its AI drug discovery and development efforts. Also, Flagship revealed new global health and AI initiatives, Seawolf launched with $100m and Marrow emerged with $173m.
Scrip - November 17, 2026
Sellas Finds Path Forward With GPS Results In Acute Myeloid Leukemia
The biotech announced positive topline results for the WT1-targeting cancer vaccine galinpepimut-S (GPS) in maintenance treatment of AML.
Scrip - November 17, 2026
The biotech announced positive topline results for the WT1-targeting cancer vaccine galinpepimut-S (GPS) in maintenance treatment of AML.
Scrip - November 17, 2026
Roche’s Wilserdly Joins Oral SERD Market, But Adjuvant Indication Still Pending
Roche’s giredestrant was approved by the US FDA for the treatment of ESR1-mutated, ER+, HER2- breast cancer, joining three other oral SERDs on the market.
Scrip - November 17, 2026
Roche’s giredestrant was approved by the US FDA for the treatment of ESR1-mutated, ER+, HER2- breast cancer, joining three other oral SERDs on the market.
Scrip - November 17, 2026
Jefferies 2026: CEO Goldsmith Talkin’ ‘Bout A Revolution
Rasonque is off to a flyer for pancreatic cancer but company chief Mark Goldsmith has warned that stunning sales of nearly $200m in just five weeks on the market are tricky to interpret as a sign for long-term success.
Scrip - November 17, 2026
Rasonque is off to a flyer for pancreatic cancer but company chief Mark Goldsmith has warned that stunning sales of nearly $200m in just five weeks on the market are tricky to interpret as a sign for long-term success.
Scrip - November 17, 2026
Chinese Companies Will Be Our Biggest Rivals By 2030, Says Pfizer CEO
But the US giant believes its ongoing cost-savings and rapid uptake of AI will help it compete with China’s low-cost, high-speed R&D.
Scrip - November 17, 2026
But the US giant believes its ongoing cost-savings and rapid uptake of AI will help it compete with China’s low-cost, high-speed R&D.
Scrip - November 17, 2026
Pipeline Watch: Two Approvals And Seven Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - November 17, 2026
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - November 17, 2026
Uniquity’s Phase II Solrikitug Data In EoE Rival Amgen/AstraZeneca’s Tezspire
Private Uniquity Bio plans to take its TSLP inhibitor solrikitug into a single Phase III study in eosinophilic esophagitis financed by existing backer Blackstone and potentially other investors.
Scrip - November 17, 2026
Private Uniquity Bio plans to take its TSLP inhibitor solrikitug into a single Phase III study in eosinophilic esophagitis financed by existing backer Blackstone and potentially other investors.
Scrip - November 17, 2026
Medtronic Wins FDA General Surgery Clearance For Hugo, Expanding Challenge To Da Vinci
The FDA's clearance of Medtronic’s Hugo for six general surgery procedures expands its US reach into a market of about 3.5 million annual procedures, strengthening its position against Intuitive Surgical’s da Vinci platform. Analysts say the clearance could be a catalyst for broader adoption.
Medtech Insight - November 17, 2026
The FDA's clearance of Medtronic’s Hugo for six general surgery procedures expands its US reach into a market of about 3.5 million annual procedures, strengthening its position against Intuitive Surgical’s da Vinci platform. Analysts say the clearance could be a catalyst for broader adoption.
Medtech Insight - November 17, 2026
HLTH 2026: NuraLogix Introduces New Compact Smart Mirror To Predict Health Risks
NuraLogix debut the Anura MagicMirror Mini at HLTH 2026, a compact smart mirror that uses facial blood-flow imaging and AI to estimate vitals and health-risk indicators from a 30-second selfie. Aimed at businesses at about $4,000, it will get a roughly $1,000 consumer version at CES in January 2027.
Medtech Insight - November 17, 2026
NuraLogix debut the Anura MagicMirror Mini at HLTH 2026, a compact smart mirror that uses facial blood-flow imaging and AI to estimate vitals and health-risk indicators from a 30-second selfie. Aimed at businesses at about $4,000, it will get a roughly $1,000 consumer version at CES in January 2027.
Medtech Insight - November 17, 2026
Combination Product Group Asks FDA To Tighten Device Terms In Container Closure Draft
The Combination Products Coalition asked FDA to define key terms and loosen fixed testing language in its container closure draft for drug-device products, while the Personal Care Products Council argued against language opposing recycled plastic content.
Medtech Insight - November 17, 2026
The Combination Products Coalition asked FDA to define key terms and loosen fixed testing language in its container closure draft for drug-device products, while the Personal Care Products Council argued against language opposing recycled plastic content.
Medtech Insight - November 17, 2026
Medtronic’s Contego Deal Demonstrates Fruits Of Staged M&A Strategy
Medtech giant’s acquisition spree continues with addition of stroke prevention system into its portfolio, setting Medtronic up to compete with similar products from Boston Scientific and InspireMD.
Medtech Insight - November 17, 2026
Medtech giant’s acquisition spree continues with addition of stroke prevention system into its portfolio, setting Medtronic up to compete with similar products from Boston Scientific and InspireMD.
Medtech Insight - November 17, 2026
White House Pulls Overton’s US FDA Commissioner Nomination Despite Cassidy Seeing Path
Outgoing Senate Health, Education, Labor and Pensions Committee Chair Bill Cassidy said Heidi Overton’s nomination for FDA commissioner died because of the White House, not a lack of votes.
HBW Insight - November 18, 2026
Outgoing Senate Health, Education, Labor and Pensions Committee Chair Bill Cassidy said Heidi Overton’s nomination for FDA commissioner died because of the White House, not a lack of votes.
HBW Insight - November 18, 2026
Proposed US Rule May Boost Supplement Industry Chances In ‘Race To Market’ For New Ingredients
FDA doesn’t signal end to “race to market” supplement industry is up against to introduce additional dietary ingredients before they’re approved as drugs but suggests ingredients already used in drugs can be shown to qualify for exemptions to “exclusion clause.”
HBW Insight - November 18, 2026
FDA doesn’t signal end to “race to market” supplement industry is up against to introduce additional dietary ingredients before they’re approved as drugs but suggests ingredients already used in drugs can be shown to qualify for exemptions to “exclusion clause.”
HBW Insight - November 18, 2026
Harry’s Marketer Questions NARB Appeals Process Amid FTC Referral
Mammoth Brands’ reluctance to comply with NARB’s recommendations in an appeal brought forward by Procter & Gamble will result in the self-regulatory appeals body referring the matter to the FTC.
HBW Insight - November 18, 2026
Mammoth Brands’ reluctance to comply with NARB’s recommendations in an appeal brought forward by Procter & Gamble will result in the self-regulatory appeals body referring the matter to the FTC.
HBW Insight - November 18, 2026
Fresenius Kabi Enters Canada’s Crowded Denosumab Biosimilar Market With Oncology Pre-Filled Syringe
Fresenius Kabi has launched its denosumab biosimilars Bomyntra and Conexxence in Canada, saying it is the only biosimilar maker with a pre-filled syringe for oncology.
Generics Bulletin - November 17, 2026
Fresenius Kabi has launched its denosumab biosimilars Bomyntra and Conexxence in Canada, saying it is the only biosimilar maker with a pre-filled syringe for oncology.
Generics Bulletin - November 17, 2026
Rosemont Bolsters US Ambitions By Paying $56m For Aytu BioPharma
Rosemont Pharmaceuticals has furthered its international expansion strategy by striking a deal worth $56m to acquire US specialty player Aytu BioPharma.
Generics Bulletin - November 17, 2026
Rosemont Pharmaceuticals has furthered its international expansion strategy by striking a deal worth $56m to acquire US specialty player Aytu BioPharma.
Generics Bulletin - November 17, 2026
Towa’s Core Business Growth Offset By Sunsho Pharmaceuticals’ Struggles
As Towa announces interim results for the six-month period ending Sept. 30, 2026, concerns continue to mount over the Japanese firm’s struggling subsidiary, Sunsho Pharmaceuticals.
Generics Bulletin - November 17, 2026
As Towa announces interim results for the six-month period ending Sept. 30, 2026, concerns continue to mount over the Japanese firm’s struggling subsidiary, Sunsho Pharmaceuticals.
Generics Bulletin - November 17, 2026
Strategic Intent: Praxis CEO On “Unlearning,” AI And Launching Two Neuroscience Drugs At Once
In this episode of Strategic Intent, Praxis CEO Marcio Souza explains how unlearning, AI fluency and patient-centered trial design shaped its turnaround as it readies two very different neuroscience drug launches.
In Vivo - November 17, 2026
In this episode of Strategic Intent, Praxis CEO Marcio Souza explains how unlearning, AI fluency and patient-centered trial design shaped its turnaround as it readies two very different neuroscience drug launches.
In Vivo - November 17, 2026




